CR20220641A - Compuestos de insulina acilada de acción temporal prolongada - Google Patents

Compuestos de insulina acilada de acción temporal prolongada

Info

Publication number
CR20220641A
CR20220641A CR20220641A CR20220641A CR20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A CR 20220641 A CR20220641 A CR 20220641A
Authority
CR
Costa Rica
Prior art keywords
compounds
acylated insulin
extended time
time action
insulin compounds
Prior art date
Application number
CR20220641A
Other languages
English (en)
Inventor
Valdislav Kisselev
David Benjamin Flora
Wen Liu
Francisco Alcides VALENZUELA
Seamus Patrick Brennan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20220641A publication Critical patent/CR20220641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos descritos en la presente se refieren al tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilada de acción temporal prolongada que reducen la glucosa en sangre, composiciones farmacéuticas que contienen tales compuestos, usos terapéuticos de tales compuestos y un compuesto intermediario usado para fabricar los compuestos de insulina acilada.
CR20220641A 2020-05-15 2021-05-13 Compuestos de insulina acilada de acción temporal prolongada CR20220641A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025463P 2020-05-15 2020-05-15
PCT/US2021/032144 WO2021231676A1 (en) 2020-05-15 2021-05-13 Extended time action acylated insulin compounds

Publications (1)

Publication Number Publication Date
CR20220641A true CR20220641A (es) 2023-01-19

Family

ID=78524979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220641A CR20220641A (es) 2020-05-15 2021-05-13 Compuestos de insulina acilada de acción temporal prolongada

Country Status (16)

Country Link
US (1) US20230174609A1 (es)
EP (1) EP4149516A1 (es)
JP (1) JP7456007B2 (es)
KR (1) KR20230009499A (es)
CN (1) CN115867308A (es)
AU (1) AU2021273262A1 (es)
BR (1) BR112022022885A2 (es)
CA (1) CA3177905A1 (es)
CL (1) CL2022003187A1 (es)
CO (1) CO2022016338A2 (es)
CR (1) CR20220641A (es)
EC (1) ECSP22087958A (es)
IL (1) IL297976A (es)
MX (1) MX2022014309A (es)
PE (1) PE20230832A1 (es)
WO (1) WO2021231676A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AU1111799A (en) 1997-10-24 1999-05-17 Eli Lilly And Company Fatty acid-acylated insulin analogs
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
WO2017005765A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل

Also Published As

Publication number Publication date
KR20230009499A (ko) 2023-01-17
CO2022016338A2 (es) 2022-11-29
IL297976A (en) 2023-01-01
JP7456007B2 (ja) 2024-03-26
CN115867308A (zh) 2023-03-28
CA3177905A1 (en) 2021-11-18
EP4149516A1 (en) 2023-03-22
CL2022003187A1 (es) 2023-03-03
AU2021273262A1 (en) 2022-12-08
US20230174609A1 (en) 2023-06-08
WO2021231676A1 (en) 2021-11-18
ECSP22087958A (es) 2022-12-30
PE20230832A1 (es) 2023-05-19
BR112022022885A2 (pt) 2022-12-20
MX2022014309A (es) 2022-12-07
JP2023526069A (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
CR20220641A (es) Compuestos de insulina acilada de acción temporal prolongada
PH12019502655A1 (en) Acylated insulin compound
NO20084919L (no) Oksadiazolidindionforbindelse
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2019007119A (es) Preparado oral del activador de glucocinasa y preparacion del mismo.
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
PH12019501251A1 (en) Novel phenyl propionic acid derivatives and uses thereof
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
RS20060015A (en) Substituted thiazole- benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
MX2021010988A (es) Derivados de insulina sensibles a la glucosa.
MX2020014262A (es) Composicion farmaceutica que comprende un agente basico poco soluble.
EA202192483A1 (ru) Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
WO2019066359A3 (ko) 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
MX2022012033A (es) Agente terapeutico para infeccion por coronavirus.